https://www.insideprecisionmedicine.com/topics/oncology/leukemia/promising-menin-inhibitor-results-from-leukemia-trial-published/
Syndax’s revumenib shows promise in advanced acute leukemias with KMT2A rearrangements or mutant NPM1, according to findings published this week in Nature.
Create an account
or login to join the discussion